Molecular Therapeutics Research Program

Molecular Therapeutics Research Program

Mission

The underlying mission of the Molecular Therapeutics (MT) Program is to translate laboratory findings to the clinic so as to improve the lives of patients with cancer by identifying new molecules, targets and strategies for treating cancer. This highly interactive program includes a cross section of laboratory-based scientists and physicians at Karmanos who meet regularly through programmatic activities, and serve as co-investigators on research grants and investigator-initiated clinical trials.

The MT Program’s overriding goal is to integrate basic and translational scientists working broadly in areas of drug development, new or established therapeutic targets or pathways, and cellular and genetic biomarkers of cancer, with physicians conducting interventional treatment trials at the Karmanos Cancer Institute.  

Scientific Themes

  1. Identify and validate novel therapeutics, targets and pathways for selective tumor targeting.  
  2. Identify cellular/molecular determinants and biomarkers of tumor response.  
  3. Validate clinical effectiveness of new agents in interventional treatment trials.

Program Activities

The MT Program leadership actively supports:

  • Basic-clinical collaborations and translational research through the monthly program meetings
  • Molecular Therapeutics Special Seminars
  • Focused retreats
  • Small working groups or topical conferences
  • An annual Molecular Therapeutics Program Retreat
  • Targeted internal grants with emphasis on collaboration and translational science

Program Leaders

  • Larry Matherly, Ph.D.

    Eunice and Milton Ring Endowed Chair for Cancer Research
    Professor & Director, Cancer Biology Graduate Program
    Associate Center Director for Basic Sciences
    Molecular Therapeutics Program Leader
    Barbara Ann Karmanos Cancer Institute
    Wayne State University School of Medicine
    matherly@karmanos.org

  • Philip Philip, M.D., Ph.D.

    Kathryn Cramer Endowed Chair in Cancer Research
    Vice President of Medical Affairs
    Multidisciplinary Team Leader, GI and Neuroendocrine Tumor
    Molecular Therapeutics Program Co-Leader
    Barbara Ann Karmanos Cancer Institute
    Professor, Department of Oncology
    Wayne State University School of Medicine
    philipp@karmanos.org

     

  • Jeffrey Zonder, M.D.

    Leader, Multiple Myeloma Sub-Committee
    Molecular Therapeutics Program Co-Leader
    Barbara Ann Karmanos Cancer Institute
    Professor, Departments of Hematology & Oncology
    Wayne State University School of Medicine
    zonderj@karmanos.org

The Latest From Karmanos Cancer Institute

News

Karmanos Cancer Institute presents 2021 Heroes of Cancer Awards

The Barbara Ann Karmanos Cancer Institute is pleased to announce the winners of its 2021 Heroes of Cancer Awards. This year's event celebrates Kar...

Read More

Karmanos Cancer Institute partners with The Toledo Clinic to establish a new cancer center in Northwest Ohio

The Barbara Ann Karmanos Cancer Institute is pleased to announce that it has entered into a partnership with The Toledo Clinic to establish a new ...

Read More

Father with colorectal cancer gives credit to daughter for saving his life

After serving for 20 years in the United States Navy as a submarine sailor, John Lacks retired and transitioned to life with his family, including...

Read More